SCT 800

Drug Profile

SCT 800

Alternative Names: SCT800

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sinocelltech
  • Class Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 29 Sep 2016 Sinocelltech plans a phase III trial for Haemophilia A (In adolescents, In adults, Treatment-experienced) in China (NCT02921945)
  • 20 Sep 2016 Sinocelltech plans a phase I trial for Haemophilia A (In children, In adults, Treatment-experienced) in China (NCT02888223)
  • 25 Jan 2016 Pharmacodynamics data from a preclinical studies in Haemophilia A released by Sinocelltech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top